A brief introduction to China's new Drug Administration Law and its impact on medications for rare diseases

被引：5
|
作者：
Wang, Yueqiang [1 ]
Chen, Duo [1 ]
He, Jiangjiang [1 ,2 ]
机构：
[1] Shanghai Med Informat Ctr, Shanghai Hlth Dev Res Ctr, 1477 Beijing W Rd, Shanghai 200040, Peoples R China
[2] Fudan Univ, Sch Publ Hlth, Shanghai, Peoples R China
来源：
INTRACTABLE & RARE DISEASES RESEARCH | 2019年 / 8卷 / 04期
关键词：
Drug Administration Law; characteristics of legislation; implementation of the law; rare disease; orphan drug;
D O I：
10.5582/irdr.2019.01133
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The Drug Administration Law of the People's Republic of China (amended in August 2019) is a major piece of legislation governing drug administration in China. This law seeks to improve health legislation; to achieve this, it defines the concepts of fake drugs and inferior drugs and their differences, it emphasizes the regulation of reliability, it standardizes online drug sales, it encourages technological innovation, and it specifies legal liability and punishment through legislative amendments. The Drug Administration Law is characteristic of responsive legislation, and it guarantees a right to health for citizens. The law provides for priority review and approval of new drugs for diseases like rare diseases, it encourages the domestic manufacturing and development of new drugs for rare diseases, and it provides a firm legal basis for medications to treat rare diseases under the Healthy China strategy.
引用
收藏
页码：226 / 230
页数：5
相关论文
共 36 条
  • [31] Measuring the Policy Effectiveness of China's New-Energy Vehicle Industry and Its Differential Impact on Supply and Demand Markets
    Wang, Di
    Li, Yuman
    [J]. SUSTAINABILITY, 2022, 14 (13)
  • [32] CONVERSION EFFICIENCY OF NEW AND OLD KINETIC ENERGY AND ITS IMPACT FACTORS IN CHINA'S CONSTRUCTION INDUSTRY BASED ON MALMQUIST INDEX METHOD
    Zhou, Weizhong
    Li, Qihui
    Cui, Xiaoqing
    [J]. JOURNAL OF ENVIRONMENTAL PROTECTION AND ECOLOGY, 2022, 23 (03): : 1309 - 1320
  • [33] New evidence on the impact of China's New Rural Cooperative Medical Scheme and its implications for rural primary healthcare: multivariate difference-in-difference analysis
    Babiarz, Kimberly Singer
    Miller, Grant
    Yi, Hongmei
    Zhang, Linxiu
    Rozelle, Scott
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2010, 341 : 929
  • [34] The Infectious Diseases Society of America's 10 x ′20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 x ′20 a Possibility?
    Talbot, George H.
    Jezek, Amanda
    Murray, Barbara E.
    Jones, Ronald N.
    Ebright, Richard H.
    Nau, Gerard J.
    Rodvold, Keith A.
    Newland, Jason G.
    Boucher, Helen W.
    [J]. CLINICAL INFECTIOUS DISEASES, 2019, 69 (01) : 1 - 11
  • [35] Research on the Impact of Environmental Regulation on Green Technology Innovation from the Perspective of Regional Differences: A Quasi-Natural Experiment Based on China's New Environmental Protection Law
    Liu, Qin
    Zhu, Ying
    Yang, Weixin
    Wang, Xueyu
    [J]. SUSTAINABILITY, 2022, 14 (03)
  • [36] A Triple-Difference Approach to Re-Evaluating the Impact of China's New Cooperative Medical Scheme on Incidences of Chronic Diseases Among Older Adults in Rural Communities
    Chen, Qihui
    Chu, Xueling
    Wang, Suzhen
    Zhang, Bo
    [J]. RISK MANAGEMENT AND HEALTHCARE POLICY, 2020, 13 : 643 - 659
1234